Q-omics provides the consensus-scored IL10RB-DT profile across patient tissues and cancer cell-line models. IL10RB-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL10RB-DT is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, IL10RB-DT RNA expression shows 17,999 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where IL10RB-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL10RB-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL10RB-DT survival associations across molecular data types. IL10RB-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL10RB-DT RNA expression–survival associations across cancer types. High IL10RB-DT expression shows unfavorable associations in UVM, KIRC and ACC, but favorable associations in LUAD, SKCM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IL10RB-DT RNA expression.
This table summarizes IL10RB-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IL10RB-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL10RB-DT shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, KIRP, BLCA and STAD. The KIRC box plot shows higher IL10RB-DT RNA expression in tumor versus normal tissue (log2 FC = +0.769, t-test p < 0.001).
This table shows molecular features associated with IL10RB-DT in patient tissues and cancer cell lines. In patient samples, IL10RB-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
